At Selexis, diversity, inclusion, and equality have been a part of our DNA since our founding. Having varied perspectives drives innovation, impacts our products and services, and helps us better serve our partners and employees. While we have more work to do to advance diversity and inclusion, we are constantly growing, learning, and iterating to move our company forward.
Selexis SA, a JSR Life Science Company, is the global leader in mammalian cell line development with best-in-class modular technology and highly specialized solutions that enable the life science industry to rapidly develop and commercialize innovative biotherapeutics and vaccines.
For over 20 years, Selexis has helped its partners to predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology PlatformTM is being used by global partners as one of the most robust CLD technologies worldwide.
USING INNOVATION TO DE-RISK AND ACCELERATE THE DISCOVERY AND DEVELOPMENT OF NEW THERAPEUTICS
JSR Life Sciences brings together the best-in-class capabilities of its affiliates, deep biochemical knowledge and understanding of human disease biology, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for its customers.
In 2022, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
Solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bispecific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a range of production and secretion challenges such as ensuring appropriate folding and subunit pairing.